CN115429725A - 用于抗氧化、抗炎、皮肤镇静的化妆品组合物 - Google Patents
用于抗氧化、抗炎、皮肤镇静的化妆品组合物 Download PDFInfo
- Publication number
- CN115429725A CN115429725A CN202111324822.1A CN202111324822A CN115429725A CN 115429725 A CN115429725 A CN 115429725A CN 202111324822 A CN202111324822 A CN 202111324822A CN 115429725 A CN115429725 A CN 115429725A
- Authority
- CN
- China
- Prior art keywords
- skin
- cosmetic composition
- mixed extract
- camellia
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 11
- 230000003647 oxidation Effects 0.000 title claims abstract 3
- 238000007254 oxidation reaction Methods 0.000 title claims abstract 3
- 230000001914 calming effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 47
- 240000001548 Camellia japonica Species 0.000 claims abstract description 29
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 27
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 23
- 235000018597 common camellia Nutrition 0.000 claims abstract description 22
- 241001435059 Artemisia argyi Species 0.000 claims abstract description 21
- 235000010894 Artemisia argyi Nutrition 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 10
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 8
- 235000006467 Camellia japonica Nutrition 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000003064 anti-oxidating effect Effects 0.000 claims description 7
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 241000222336 Ganoderma Species 0.000 claims description 4
- 206010039897 Sedation Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000008269 hand cream Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 230000036280 sedation Effects 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 abstract description 17
- 230000003266 anti-allergic effect Effects 0.000 abstract description 11
- -1 anti-inflammatory Substances 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 239000000932 sedative agent Substances 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 16
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 11
- 240000006891 Artemisia vulgaris Species 0.000 description 11
- 206010003645 Atopy Diseases 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- LRFDUPNLCDXZOE-UHFFFAOYSA-N camellianin b Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC=2C=3C(=O)C=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)OC1CO LRFDUPNLCDXZOE-UHFFFAOYSA-N 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 5
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 5
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- HMXJLDJMSRBOCV-UHFFFAOYSA-N Leucocyanidin Natural products OC1C(OC2C(O)C(Oc3cc(O)cc(O)c23)c4ccc(O)c(O)c4)c5c(O)cc(O)cc5OC1c6ccc(O)c(O)c6 HMXJLDJMSRBOCV-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 2
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 2
- BWPGKXYWPBQBPV-MWQJAWBESA-N Theasaponin Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)CO1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(C[C@H]14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BWPGKXYWPBQBPV-MWQJAWBESA-N 0.000 description 2
- BWPGKXYWPBQBPV-ZOADXXHESA-N Theasaponin Natural products O=C(O[C@@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@@H]7[C@H](O[C@@H]8[C@@H](O)[C@H](O)[C@H](O)CO8)[C@H](O)[C@@H](O)CO7)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C BWPGKXYWPBQBPV-ZOADXXHESA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- SBZWTSHAFILOTE-UHFFFAOYSA-N leucocianidol Natural products OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-UHFFFAOYSA-N 0.000 description 2
- 229940086558 leucocyanidin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- OMRLTNCLYHKQCK-DHGKCCLASA-N 4-nitrophenyl N-acetyl-beta-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-DHGKCCLASA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 102000005869 Activating Transcription Factors Human genes 0.000 description 1
- 108010005254 Activating Transcription Factors Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical group 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
用于抗氧化、抗炎、皮肤镇静的化妆品组合物。本发明涉及具有抗炎、镇静功效的化妆品组合物，更详细的，涉及包含山茶花、艾叶草、灵芝混合提取物的具有优异的抗氧化、抗炎、皮肤镇静、抗过敏功效的化妆品组合物。
Description
技术领域
本发明涉及具有抗氧化、抗炎、皮肤镇静功效的化妆品组合物，更详细地，涉及包含山茶花、艾叶草、灵芝混合提取物的具有优异的皮肤渗透性以及优异的抗氧化、抗炎、皮肤镇静、抗过敏、抗特应性功效的化妆品组合物。
背景技术
皮肤是直接暴露于外界环境的表面，当暴露于各种空气污染物或紫外线等时，会诱发皮肤刺激及炎症反应或红斑等。这种反应会促进部分色素沉着和皮肤弹性丧失等，从而迅速增加皮肤老化。
一般而言，敏感性皮肤是指虽然皮脂分泌量适中但对外界刺激敏感，容易引起炎症等的对微小的物理化学变化或刺激、环境外部因素、生理内部变化的反应比正常皮肤更敏感的皮肤。作为这种敏感性皮肤的疾病，可列举出湿疹、酒渣性皮炎、接触性皮炎等，其中，特应性皮炎是最具代表性的疾病。
特应性皮炎是过敏人群中发生的一种代表性皮肤病，是一种非常痒的慢性炎症性皮炎，主要发生在新生儿或婴儿期，多在9～10岁自然痊愈，但最近，持续到成年的特应性病例数正在增加。据说50％左右的病例在两年内消失，25％在青春期消失，剩下的25％即使到了成年也不会消失。并且，近年来，由于环境因素和压力等而在成年期首次发生特应性的病例数也在迅速增加。据韩国医学界称，整个韩国人口中约有15％患有特应性皮炎。
由于皮肤的水分没有得到保护，它开始是皮肤干燥症，伴随着极度的瘙痒、发红、肿胀和瘙痒。因此，如果一直抓挠皮肤，它会发展成由指甲之间的细菌引起的炎症性疾病，严重时会导致疮和结痂。
炎症反应是当对生物体或组织施加带来如物理作用、化学物质或细菌感染等任何有机变化的入侵时，修复和再生受损区域的机制，一旦施加刺激，如组胺、5-羟色胺、缓激肽、前列腺素、羟基二十碳四烯酸(HETE)和白三烯等血管活性物质会局部游离，导致血管侵袭增加，从而引起炎症。
与大多数疾病一样，皮肤病也伴随着炎症反应，作为代表性的皮肤病的过敏性接触性皮炎、牛皮癣、特应性皮炎等为由作为免疫细胞的T细胞介导的炎症性疾病。因此，抗炎药物必须应用于主要皮肤病的管理和治疗。甾体类抗炎药用于治疗这种炎症性疾病，但甾体类药物有许多副作用，限制了它们的使用。非甾体类抗炎药与天然抗菌剂一样，可以从天然植物中获得，不仅在韩医学和中医学，而且在西医学中也已经进行着大量的研究。
炎症反应是在受损细胞或组织中诱导的免疫反应之一，是一种通过与局部血管和体液中的各种免疫细胞相互作用来诱导酶激活、介质分泌、体液浸润、细胞移动和组织破坏等的一系列复杂的生物防御反应。
一般而言，炎症反应的特征是促炎细胞因子(pro-inflammatory cytokine)的过度表达，促炎细胞因子是促进炎症反应的细胞因子(cytokine)，并且由于促炎和抗炎细胞因子(pro&anti inflammatory cytokine)的失衡而诱发各种形式的炎性疾病。参与初始炎症反应的促炎细胞因子的分泌和生成是由免疫细胞生长及分化过程中的细胞内基因表达编程和细胞外部刺激决定的，像这样生成的促炎细胞因子通过激活如NF-kb及AP-1等转录因子来诱导参与炎症反应的蛋白质的基因表达。
因此，为了防止皮肤炎症反应，需要通过防止由各种原因引起的促炎细胞因子的过度表达来防止皮肤损伤，需要通过活跃的新陈代谢进行再生及增殖来恢复已经受损的细胞。因此，对使用天然提取物开发具有抗氧化、抗炎、皮肤镇静、抗过敏、抗特应性等功能的化妆品的兴趣和研究正在持续地进行。
因此，本发明人为了防止皮肤炎症反应，提高抗炎、镇静效果效果等，反复进行了研究，通过结果确认，当包含山茶花提取物、艾叶草提取物、灵芝提取物的混合物作为有效成分时，与单独使用这些成分时相比，它们具有更优异的抗氧化、抗炎、镇静、抗过敏、抗特应性功效。
现有技术文献
专利文献
专利文献1：韩国授权专利第10-1831883号
专利文献2：韩国授权专利第10-1831876号
发明内容
技术问题
对之前已授予专利权的艾叶草提取物相关专利发明(韩国授权专利第10-1831876号)中的特应性皮炎改善效果的增加方法进行持续研究，通过结果可知，若混合使用源自某些天然植物的提取物，则可以在副作用不存在或最小的情况下增加特应性皮炎及镇静、抗炎效果，从而完成本发明。即，本发明提供包含山茶花、艾叶草、灵芝混合提取物作为有效成分的具有抗炎、镇静、抗过敏、抗特应性功效的化妆品组合物。
解决问题的方案
为了实现上述目的，本发明的具有抗炎、镇静功效的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物。
并且，相对于化妆品组合物的总重量，本发明的具有抗炎、镇静功效的化妆品组合物包含0.01～10重量百分比的山茶花、艾叶草、灵芝混合提取物，优选地，包含0.1～5重量百分比，更优选地，包含1～3重量百分比。
若上述混合提取物的含量小于0.01重量百分比，则存在有效性能发挥受限的问题，若大于10重量百分比，则在剂型化及剂型稳定化方面存在问题。
并且，本发明的具有抗氧化功效的化妆品组合物中，上述山茶花、艾叶草、灵芝的混合比例(重量百分比)为山茶花：艾叶草：灵芝＝1：1：1(重量百分比)～2：1：2(重量百分比)。
并且，本发明的化妆品组合物实现为选自由润肤液、柔肤水、爽肤水、收敛剂、护肤液、乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底、精华液、营养精华液、面膜、香皂、洗面奶、洁面乳、洁面霜、润肤露及沐浴露组成的组中的一种以上剂型。
并且，本发明的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物作为有效成分，因此具有抗炎、镇静、抗过敏、抗特应性功效。
发明的效果
本发明的具有抗炎、镇静功效的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物作为有效成分，因此具有防止皮肤损伤并使皮肤健康的抗炎、皮肤镇静功效。
具体实施方式
以下，将描述本发明的优选实施例。尽管在下面描述了本发明，但如果判断为相关公知功能或结构的具体描述可能不必要地混淆本发明的主旨，则将省略其详细描述。
本发明的具有抗炎、镇静功效的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物作为有效成分，因此具有防止皮肤损伤和防止老化并使皮肤健康的抗炎、镇静功效以及抗过敏、抗特应性功效的化妆品组合物。
山茶(Camellia Japonica L.)属于山茶科常绿阔叶乔木，其白色茎上长出许多小枝，形成长椭圆形或半球形的树形，树皮为灰白色，光滑，叶互生，椭圆形或长椭圆形，有细锯齿。长为5～12cm，宽为3～7cm，表面为深绿色。花为鲜红色或白色，有5片花瓣，一般认为是红茶色，11月至次年3月开花，10月底左右种子成熟。
这种山茶花中含有单宁(tannin)、山茶素(camelliin)及无色花青素(leucocyanidin)等成分，种子中存在66％的油，其主要成分为油酸甘油酯。并且，种子中存在山茶花苷(C18H34O7)、茶花皂苷(C58H92O25)(科学百科全书出版社，草药的成分和用途，1999)。已知山茶素具有强心作用，茶花皂苷具有溶血作用，山茶油用作油性软膏的基质。并且，据报道，山茶花(山茶花：本草名)在民间用作用于呕血、肠风下血的止血剂，使用红色花朵，研成粉末，与童尿、姜汁和酒精一起服用，抗原虫作用及解痉作用(Namba et al.，Shoyakugaku Zasshi，38(3)，pp.263-264，1984)、牙结石形成抑制下效果(Yoshikawaetal.，Chem.Pharm.Bull.42(3)，p.742，1994)、酒精吸收抑制(Mori and Nishimiya，日本公开专利公报63-303910，12，Dec.，1988)、美白效果(Sakata et al.，Mem.Fac.Agr.Kagoshima Univ.，17，pp.79-94，1981)等生理活性。
在本发明中利用具有优异收敛功效的山茶(Camellia Japonica L.)花，因此具有收缩毛孔效果、皮脂分泌量调节及强的抗菌效果和抗细菌效果，从而用作抑制皮肤的各种有害细菌的活性的收敛镇静化妆品组合物。
本发明的混合提取物中所包含的灵芝为一种包括Ganoderma lucidum在内的灵芝属(Ganaderma)菌类，广泛分布于亚洲、欧洲和北美等世界各地，作为药用蘑菇，已报道了与抗癌、抗肿瘤、高血压、糖尿病相关的多种药用功效和活性成分。据报道，灵芝中包含多种生理活性物质，因此具有抗炎症、抗氧化、抗降糖、免疫、抗肿瘤等效果。
并且，灵芝不仅提供营养，而且还具有药理作用，因此长期以来一直被认为是保健品。尤其是在亚洲大多数国家，它被认为是一种药用食品。而且，灵芝中除多糖之外还包含三萜(tritepene)、核苷(nucleoside)、类固醇(steroid)、脂肪酸(fatty acid)、生物碱(alkaloid)、蛋白质、氨基酸、无机盐等多种物质，其中，高分子物质(多糖等)和低分子物质(三萜等)多种多样。据报道，低分子物质具有抗炎症、抗氧化、肝细胞保护、抗过敏、抗高血压、降低胆固醇及抑制血小板聚集等活性，高分子物质具有降血压、净化血液、改善高血脂、降血糖、免疫以及抗肿瘤等效果。
灵芝中含有0.3～0.4％的麦角甾醇溶菌酶、酸性蛋白酶、多糖、有机酸、树脂、香豆素、甘露醇、生物碱等。东医治疗中用作用于神经衰弱、失眠、消化不良的补品和镇静剂。据古东医文献记载，长期吃灵芝，身体会变得强壮，不会变老。它还有助于活力，使骨折的骨头变硬，并改善面部颜色。
本发明中的艾叶草的艾叶是指将艾蒿的叶和嫩茎干燥而得的药材，表示艾蒿的“艾”是相传用了具有切的意思的“乂”字，意为切病，并且，又叫“冰台”，因为相传如果把冰块切开做一个放大镜，拿着它，对准太阳，把艾叶草放在灯下，就可以点亮它。因为它是灸法的主要材料，治百病，所以又叫“灸草”。
艾叶使气血和经脉温热，因此对子宫及小腹虚寒所致的子宫出血、孕期出血、吐血、流鼻血、咯血具有止血反应。并且，用于表现出下焦虚寒、小腹冷痛的症状以及月经不调、经痛、帶下等，对湿疹、皮肤瘙痒也有效果。
艾蒿(Artemisia，Mugwort)菊科多年生草本植物，普遍生长于韩国各地的山区和田野中，繁殖力强。艾蒿不仅以其独特的味道改善色泽和风味，而且由于富含矿物质，它还是一种碱性食品，已知叶绿素具有抗癌作用、改善血液循环，用于熏蒸，并且具有止血作用、降血压作用、抗过敏作用(Sung，2009)和抗菌作用(Jung，2005；Lee，2010；Park&Park，1994)。艾蒿含有蓝绿色叶绿素和黄色黄酮等作为色素。叶绿素中的蓝绿色叶绿素a和黄绿色叶绿素b的比例约为2～3：1，中性时呈绿色，酸性时失去Mg2+原子，呈橄榄色，碱性时甲基和植醇酯被去除，变为亮绿色，叶绿素形成植醇和酯，故为脂溶性。艾蒿中还含有黄色黄酮，黄酮属于酚类，是由两个苯环与三个碳原子连接而成的具有酮的化合物的总称，分为黄酮、黄酮醇、花青素等，每种都有很多衍生物且具有抗菌作用。
本发明的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物。
更具体地，相对于化妆品组合物的总重量，优选地，本发明的化妆品组合物包含0.01～10重量百分比的山茶花、艾叶草、灵芝混合提取物，更优选地，包含0.1～5重量百分比，更加优选地，包含1～3重量百分比。
若上述混合提取物的含量小于0.01重量百分比，则存在有效性能发挥受限的问题，若大于10重量百分比，则在剂型化及剂型稳定化方面存在问题。
并且，本发明的具有抗氧化功效的化妆品组合物中，上述山茶花、艾叶草、灵芝的混合比例(重量百分比)为山茶花：艾叶草：灵芝＝1：1：1(重量百分比)～2：1：2(重量百分比)。
并且，本发明的具有抗炎、镇静功效的化妆品组合物实现为选自由润肤液、柔肤水、爽肤水、收敛剂、护肤液、乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底、精华液、营养精华液、面膜、香皂、洗面奶、洁面乳、洁面霜、润肤露及沐浴露组成的组中的一种以上剂型。
并且，本发明的化妆品组合物包含山茶花、艾叶草、灵芝混合提取物作为有效成分，因此具有抗炎、镇静、抗过敏、抗特应性功效。
以下，通过实施例等详细说明本发明的结构及效果，但本发明并不限定于此。
实施例1至实施例10：混合提取物的制备
向按照下列表1的试样混合比例(山茶花：艾叶：灵芝)混合的100g的原料中加入1kg的50％乙醇进行混合，在60℃的温度下提取经混合的提取物3小时，冷却，过滤得0.45μm。将上述滤液减压浓缩及真空干燥来获得粉末。
表1
实验例1：自由基清除活性测定实验
利用DPPH法测定在上述实施例1至实施例10中制备的各混合提取物的自由基清除活性。
DPPH法是使用称为DPPH(2,2-Di(4-tert-octylphenyl)-1-1picrylhydrazylfree radical)的游离基并通过还原力来测定自由基清除活性的方法。将因DPPH被受试物质还原而降低吸光度的程度与空白试液的吸光度进行比较，在560nm的波长处测定自由基清除率。
为了测定DPPH自由基清除活性，准备0.5％浓度的提取物。将上述浓度的提取物分别放入96孔板中，向其中添加用100μM的甲醇溶液制备的DPPH至溶液的总体积达到200μl。在37℃的温度下放置30分钟后，在560nm的波长处进行测定。
数学公式1
自由基清除活性(％)＝{100-(B/A)}×100
A：未处理本发明的试样的对照组孔的吸光度，
B：处理本发明的试样的实验组孔的吸光度，
表2
| 试样名 | 抗氧化效果(％) |
| 实施例1 | 31.6 |
| 实施例2 | 39.1 |
| 实施例3 | 67.7 |
| 实施例4 | 59.4 |
| 实施例5 | 49.4 |
| 实施例6 | 51.0 |
| 实施例7 | 68.8 |
| 实施例8 | 70.2 |
| 实施例9 | 57.2 |
| 实施例10 | 62.5 |
由上述表2可知，实施例7、实施例8中的自由基清除活性最优异。
实验例2：试样的细胞毒性
通过MTT法(MTT assay)确认在上述实施例1至10中制备的各混合提取物的细胞毒性。首先向96孔板(well plate)中以5×104细胞/孔(cell/well)进行分配，24小时后，添加各浓度的溶解在DMSO中的试样(sample)。24小时后，去除培养基，然后每孔(well)添加40μL的MTT试剂(in PBS 2.5mg/mL)，在培养箱(incubator)中反应4小时后再去除上清液。每孔分配100μL的DMSO完全溶解。利用分光光度计测定在540nm波长处的吸光度。
表3
| 试样名 | 细胞存活率(％) |
| 实施例1 | 97 |
| 实施例2 | 95 |
| 实施例3 | 85 |
| 实施例4 | 87 |
| 实施例5 | 88 |
| 实施例6 | 90 |
| 实施例7 | 96 |
| 实施例8 | 98 |
| 实施例9 | 90 |
| 实施例10 | 87 |
试样的细胞存活率在实施例7、实施例8中同样表现出优异。
表2显示，实施例3的自由基活性清除能力与实施例7、实施例8相似，同样优异，但表3显示，细胞存活率没有如实施例7、实施例8那样优异。
并且，表3显示实施例1的细胞存活率高，但表2显示自由基活性清除能力显著低。
因此，实施例7、实施例8为自由基活性清除能力及细胞存活率优异的例子。
因此，根据上述表2和表3的结果，对实施例7、实施例8进行后续实验。
实验例3：NO生成量的测量
通过确认对已知在诱发炎症中起重要作用的NO生成的效果来确认在上述实施例7和实施例8中得到的混合提取物的抗炎活性效果。通过测量细胞(cell)的上清液(supernatant)中以亚硝酸盐(nitrite)和硝酸盐(nitrate)形式存在的NO量来测量一氧化氮(Nitric Oxide)。使用作为亚硝酸盐还原为硝酸盐后的安全形式的格里斯试剂(griessreagent)，当RAW264.7细胞的汇合度(confluence)为80％时，使用PBS清洗(washing)两次后，使用无血清培养基培养18小时以上，然后按浓度处理试样并培养1小时后，处理1μg/mL的脂多糖(lipopolysacchride，LPS)并培养24小时。取培养液的上清液与格里斯试剂反应后，使用酶标仪(ELISA reader)测定在540nm波长处的吸光度，以百分比表示NO生成率。为了确认作为炎症反应的代表性因子的NO的生成是否受到抑制，对RAW264.7细胞处理1μg/mL的脂多糖，然后2小时后，按浓度处理提取物。培养18小时后，测量培养液中的NO量。
表4
由上述表4可知，当试样浓度低时，NO生成量高，当浓度高时，NO生成量低。
实验例4：β-氨基己糖苷酶释放(β-hexosaminidase release)抑制量的测定
通过测定已知与组胺(Histamine)一起作为重要介质的β-氨基己糖苷酶(β-hexosaminidase)来确认在上述实施例7和实施例8中得到的混合提取物的抗过敏活性效果。将RBL-2H3细胞悬浮于含有10％FBS的DMEM培养基(Dulbecco modified Eagle'smedium)后，将24孔板处理成每孔含有2×105个细胞，然后每孔使用100ng/ml的小鼠单克隆IgE(mouse monoclonal IgE)致敏后，在5％CO2的培养箱中培养24小时。每孔使用500μl的Tyrode缓冲液(Tyrode buffer)冲洗细胞，按浓度处理混合提取物后，在37℃、5％CO2的培养箱中培养15分钟，使用100ng/ml的DNP-BSA处理1小时。对上清液处理50μl的底物(substrate)(1mM的对硝基苯-N-乙酰-β-D-氨基葡萄糖苷(p-nitrophenyl-N-acetyl-β-D-glucosaminide))后，在37℃、5％CO2的培养箱(incubator)中培养(incubation)1小时，然后使用酶标仪(ELISA reader)测定在405nm波长处的吸光度。
表5
由表5可知，当添加本发明的混合提取物时，随着浓度的增加β-氨基己糖苷酶的释放量减少，其抑制效果优异。
制备例1：包含本发明的混合提取物的洗发剂的制备
按照下列表6中所示的组成制备包含在实施例8中得到的本发明的混合提取物的洗发剂。
表6
| 成分 | 含量(％) | |
| 1 | 95％乙醇 | 5 |
| 2 | 月桂醇聚醚硫酸铵 | 5 |
| 3 | 二十级烷基甜菜碱 | 5 |
| 4 | 烷基醚硫酸盐 | 0.5 |
| 5 | 硅酮 | 0.5 |
| 6 | 聚季铵盐 | 0.2 |
| 7 | 增味剂 | 0.2 |
| 8 | 保存剂 | 0.02 |
| 9 | 甘油 | 5 |
| 10 | 混合提取物(实施例8) | 5 |
| 11 | 纯化水 | 73.58 |
| 合计 | 100 |
制备例2：包含本发明的混合提取物的化妆水的制备
按照下列表7中所示的组成制备包含在实施例8中得到的本发明的混合提取物的化妆水。
表7
| 成分 | 含量(％) | |
| 1 | 95％乙醇 | 8 |
| 2 | 聚吡咯烷酮 | 0.05 |
| 3 | 油醇 | 0.1 |
| 4 | 聚氧乙烯单油酸酯 | 0.2 |
| 5 | 增味剂 | 0.2 |
| 6 | 对羟基苯甲酸甲酯 | 0.1 |
| 7 | 甘油 | 5 |
| 8 | 混合提取物(实施例8) | 10 |
| 9 | 纯化水 | 76.35 |
| 合计 | 100 |
制备例3：包含本发明的混合提取物的乳液的制备
按照下列表8中所示的组成制备包含在实施例8中得到的本发明的混合提取物的水包油(O/W)型乳液。
表8
Claims (5)
1.一种包含山茶花、艾叶草及灵芝混合提取物作为有效成分的用于抗氧化、抗炎、皮肤镇静的化妆品组合物。
2.根据权利要求1所述的包含山茶花、艾叶草及灵芝混合提取物作为有效成分的用于抗氧化、抗炎、皮肤镇静的化妆品组合物，其特征在于，上述混合提取物通过将山茶花、艾叶草、灵芝以1：1：1～2：1：2的重量比混合来提取而得。
3.根据权利要求1所述的包含山茶花、艾叶草及灵芝混合提取物作为有效成分的用于抗氧化、抗炎、皮肤镇静的化妆品组合物，其特征在于，上述混合提取物使用乙醇或含水乙醇提取。
4.根据权利要求1所述的包含山茶花、艾叶草及灵芝混合提取物作为有效成分的用于抗氧化、抗炎、皮肤镇静的化妆品组合物，其特征在于，相对于组合物的总重量，包含0.1重量百分比至10.0重量百分比的上述混合提取物。
5.根据权利要求1所述的包含山茶花、艾叶草及灵芝混合提取物作为有效成分的用于抗氧化、抗炎、皮肤镇静的化妆品组合物，其特征在于，上述化妆品组合物实现为选自由润肤液、柔肤水、爽肤水、收敛剂、护肤液、乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底、精华液、营养精华液、面膜、香皂、洗面奶、洁面乳、洁面霜、润肤露及沐浴露组成的组中的一种以上剂型。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210071158A KR102642582B1 (ko) | 2021-06-01 | 2021-06-01 | 동백나무꽃, 쑥잎 및 영지버섯 혼합추출물을 유효성분으로 함유하는 항산화, 항염, 항알러지용 화장료 조성물 |
| KR10-2021-0071158 | 2021-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115429725A true CN115429725A (zh) | 2022-12-06 |
| CN115429725B CN115429725B (zh) | 2024-03-08 |
Family
ID=84240315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111324822.1A Active CN115429725B (zh) | 2021-06-01 | 2021-11-10 | 用于抗氧化、抗炎、皮肤镇静的化妆品组合物 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102642582B1 (zh) |
| CN (1) | CN115429725B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117323270A (zh) * | 2023-11-29 | 2024-01-02 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485024A (zh) * | 2002-09-28 | 2004-03-31 | 戚海波 | 一种蜂蜜及在美容化妆品中的应用 |
| WO2011149007A1 (ja) * | 2010-05-27 | 2011-12-01 | 花王株式会社 | 水中油型乳化組成物 |
| CN107106586A (zh) * | 2014-10-29 | 2017-08-29 | 昭和电工株式会社 | 皮肤屏障功能改善剂和皮肤屏障功能改善用组合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101831876B1 (ko) | 2014-12-30 | 2018-02-27 | 에스케이바이오랜드 주식회사 | 이소세코타나파솔라이드를 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물 |
| KR101831883B1 (ko) | 2015-05-26 | 2018-04-16 | 에스케이바이오랜드 주식회사 | 이소세코타나파솔라이드를 유효성분으로 함유하는 가려움증 억제 및 완화용 화장료 조성물 |
-
2021
- 2021-06-01 KR KR1020210071158A patent/KR102642582B1/ko active IP Right Grant
- 2021-11-10 CN CN202111324822.1A patent/CN115429725B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485024A (zh) * | 2002-09-28 | 2004-03-31 | 戚海波 | 一种蜂蜜及在美容化妆品中的应用 |
| WO2011149007A1 (ja) * | 2010-05-27 | 2011-12-01 | 花王株式会社 | 水中油型乳化組成物 |
| CN107106586A (zh) * | 2014-10-29 | 2017-08-29 | 昭和电工株式会社 | 皮肤屏障功能改善剂和皮肤屏障功能改善用组合物 |
Non-Patent Citations (2)
| Title |
|---|
| 李朝品: "储藏中药材孳生粉螨的初步研究", 中国寄生虫病防治杂志, no. 01 * |
| 猫头鹰（福州）日用品有限公司: "SKINYOYO 山茶籽精华洗发水", 国产普通化妆品备案信息, pages 1 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117323270A (zh) * | 2023-11-29 | 2024-01-02 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
| CN117323270B (zh) * | 2023-11-29 | 2024-03-19 | 江西康一参生物科技有限公司 | 一种抗炎症多功效的人参组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220162570A (ko) | 2022-12-08 |
| KR102642582B1 (ko) | 2024-03-04 |
| CN115429725B (zh) | 2024-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150125542A1 (en) | TIE2 Activator, Vascular Endothelial Growth Factor (VEGF) Inhibitor, Angiogenesis Inhibitor, Vascular Maturing Agent, Vascular Normalizing Agent and Vascular Stabilizing Agent, and Pharmaceutical Composition | |
| KR20110112231A (ko) | 약용 잎을 활용한 쌈 발효법 및 이를 활용한 피부 외용제 조성물 | |
| KR101986186B1 (ko) | 식물추출물을 유효성분으로 포함하는 피부질환 케어용 조성물 | |
| KR101412500B1 (ko) | 대나무 통 한방 발효 추출물을 유효 성분으로 함유하는 아토피 피부 개선 화장료 조성물 및 그의 제조방법 | |
| KR20160087112A (ko) | 꽃차 및 이의 제조방법 | |
| KR100633380B1 (ko) | 특정 생약추출 혼합물을 함유하는 아토피 피부용 한방화장료 조성물 | |
| KR101300701B1 (ko) | 아토피 피부용 화장품 제조방법 | |
| KR100867514B1 (ko) | 지초 비누의 제조방법 | |
| KR102002894B1 (ko) | 천연 복합추출물을 함유하는 화장료 조성물 | |
| CN115429725B (zh) | 用于抗氧化、抗炎、皮肤镇静的化妆品组合物 | |
| KR101829891B1 (ko) | 은목서 추출물 및 사위질빵 추출물을 유효성분으로 함유하는 화장료 조성물 | |
| KR101047612B1 (ko) | 여드름 및 여드름양 발진 완화용 또는 치료용 화장료 조성물 | |
| KR102585336B1 (ko) | 탈모 예방, 개선 또는 방지용 한약재 발효물 및 이의 용도 | |
| Hoosen | The Effects of Aspalathus linearis (Rooibos Tea) on Nitric Oxide (NO) and Cytokine Activity | |
| KR101082819B1 (ko) | 천연물 유래의 아토피 피부염 완화용 기능성 조성물 | |
| KR101757457B1 (ko) | 천연 복합 추출물을 함유하는 열노화 방지 및 피부 진정용 화장료 조성물 | |
| KR101587446B1 (ko) | 아임계추출조건으로 추출한 추출물 il-s를 포함하는 항균, 보습, 가려움개선, 세라마이드증가, 항염 효과를 지닌 화장료 조성물 | |
| KR102004323B1 (ko) | 식물추출물을 유효성분으로 포함하는 두피질환 케어용 조성물 | |
| KR20120020996A (ko) | 항산화 미백 및 아토피 개선 효과를 지닌 허브 씨앗 추출물과 이를 포함하는 화장료 조성물 | |
| KR20100092922A (ko) | 나노 리포좀으로 안정화된 생약 추출물을 포함하는 피부 미백용 화장료 조성물 | |
| KR101903118B1 (ko) | 바닐라 열매, 인디언구스베리 열매 및 두송 열매 혼합추출물과 판테놀의 복합물을 함유하는 화장료 조성물 | |
| KR20090042073A (ko) | 자극완화 효능을 가진 특정의 식물추출 혼합물과 이를함유하는 알레르기성 피부용 화장료 조성물 | |
| KR100535259B1 (ko) | 생약재 추출물을 함유하는 식작용 억제제 조성물 | |
| KR101769123B1 (ko) | 천연 복합 추출물을 함유하는 아토피 피부염 개선용 화장료 조성물 | |
| KR100900197B1 (ko) | 특정 식물추출 혼합물을 함유하는 피부면역억제용 피부 외용제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |